Pacific Biosciences of California, Inc. (PACB:NASDAQ) closed at $1.99 on October 14, 2026, down 2.93% on the day. The stock trades 42.2% below its 52-week high of $3.44 and 86.0% above its 52-week low of $1.07. Over the past year, it gained 14.4%. Pacific Biosciences of California, Inc. is part of the Capital Goods sector (Biotechnology: Laboratory Analytical Instruments).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -5.24% | +48.51% | +38.19% | +14.37% | +14.37% |
In 252 trading sessions since October 14, 2025, PACB closed higher on 112 days (44%). Its best day was September 30, 2026 (+29.51%) and its worst was October 8, 2026 (-15.44%). The stock moved 10% or more in a single session 19 times.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distributors in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Find more stocks like PACB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.